Further strengthening of Poolbeg’s global intellectual property portfolio
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma is stepping up partnering discussions with multiple pharma groups
Poolbeg Pharma PLC (AIM: POLB) is stepping up partnering discussions with multiple pharma groups as it approaches a series of near-term clinical catalysts that could unlock a deal.
Poolbeg Pharma CEO speaks on BioHub podcast in London
In this episode of The BioHub Podcast, Max sits down in person in London with Jeremy Skillington, CEO of Poolbeg Pharma.
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma receives UK clearance to begin cancer immunotherapy trial
Poolbeg Pharma plc (AIM: POLB) has received Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency for its POLB 001 TOPICAL trial, marking a key regulatory milestone
Why 2026 could be a defining year for Poolbeg Pharma
Poolbeg Pharma (AIM: POLB) enters 2026 at a point where several years of methodical clinical and strategic groundwork are beginning to converge. After a deliberately measured 2025 focused on trial
Poolbeg Pharma (AIM: POLB) Significant milestone for Poolbeg’s IP portfolio
Grant of first POLB 001 cancer immunotherapy-induced CRS patent Significant milestone for Poolbeg’s global intellectual property portfolio
Poolbeg Pharma (AIM: POLB) Appointment of Dr Adrian Kilcoyne to SAB
Appointment of Dr Adrian Kilcoyne to Scientific Advisory Board
Poolbeg Pharma (AIM: POLB) POLB 001 LPS Challenge Trial Paper Published
Peer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology
Poolbeg Pharma (AIM: POLB) Letter to Shareholders – 2025 a year of progress
Letter to Shareholders – 2025 a year of great progress, with momentum maintained into 2026 when multiple value inflection points are expected
Poolbeg Pharma (AIM: POLB) POLB 001 to feature in CRS research programme
POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part